Anavex Life Sciences Corp... (AVXL)
Anavex Life Sciences Statistics
Share Statistics
Anavex Life Sciences has 85.06M shares outstanding. The number of shares has increased by 4.92% in one year.
| Shares Outstanding | 85.06M |
| Shares Change (YoY) | 4.92% |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | 34.82% |
| Shares Floating | 82.47M |
| Failed to Deliver (FTD) Shares | 543 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 19.69M, so 23.22% of the outstanding shares have been sold short.
| Short Interest | 19.69M |
| Short % of Shares Out | 23.22% |
| Short % of Float | 23.98% |
| Short Ratio (days to cover) | 10.82 |
Valuation Ratios
The PE ratio is -11.03 and the forward PE ratio is 1.94. Anavex Life Sciences's PEG ratio is 0.83.
| PE Ratio | -11.03 |
| Forward PE | 1.94 |
| PS Ratio | 0 |
| Forward PS | 0.4 |
| PB Ratio | 3.94 |
| P/FCF Ratio | -15.39 |
| PEG Ratio | 0.83 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Anavex Life Sciences Corp..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.86, with a Debt / Equity ratio of 0.
| Current Ratio | 8.86 |
| Quick Ratio | 8.86 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.36% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | -0.36% |
| Return on Assets (ROA) | -0.32% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,023,857.14 |
| Employee Count | 42 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 68.76% in the last 52 weeks. The beta is 0.94, so Anavex Life Sciences's price volatility has been higher than the market average.
| Beta | 0.94 |
| 52-Week Price Change | 68.76% |
| 50-Day Moving Average | 9.04 |
| 200-Day Moving Average | 7.35 |
| Relative Strength Index (RSI) | 43.32 |
| Average Volume (20 Days) | 1.32M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | 0 |
| Net Income | -43M |
| EBITDA | 0 |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.52 |
Balance Sheet
The company has 132.19M in cash and 0 in debt, giving a net cash position of 132.19M.
| Cash & Cash Equivalents | 132.19M |
| Total Debt | 0 |
| Net Cash | 132.19M |
| Retained Earnings | -336.07M |
| Total Assets | 124.04M |
| Working Capital | 110.92M |
Cash Flow
In the last 12 months, operating cash flow was -30.81M and capital expenditures 0, giving a free cash flow of -30.81M.
| Operating Cash Flow | -30.81M |
| Capital Expenditures | 0 |
| Free Cash Flow | -30.81M |
| FCF Per Share | -0.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AVXL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.05% |
| FCF Yield | -4.22% |
Analyst Forecast
The average price target for AVXL is $46, which is 435.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $46 |
| Price Target Difference | 435.5% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Oct 7, 2015. It was a backward split with a ratio of 1:4.
| Last Split Date | Oct 7, 2015 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 33.17 |
| Piotroski F-Score | 1 |